Biocon and Pfizer have ended their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products, citing individual priorities for their respective businesses. Both will proceed independently. The two companies will work together during a transition period help to ensure continuity of patient care. All rights licensed to Pfizer will revert to Biocon, and all insulin distributed under the brand name Univia and Glarvia will be exclusively commercially available fro...